Overall HealthNCT06989710
Radicle Health 24: A Study of Health and Wellness Products on Overall Health
A study testing Health Active Product 7.1.1 usage, Health Active Product 7.1.2 usage and Health Active Product 7.2.1 usage in people with Overall Health, run by Radicle Science at 1 site in United States.
Trial summary
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on overall health Read more about this study
- Who is it for?
- Ages 21 to 105 yearsHealthy volunteers can take part
- Conditions the study is for
- Overall Health
- What is being tested?
- Health Active Product 7.1.1 usage, Health Active Product 7.1.2 usage and Health Active Product 7.2.1 usage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,700 participants
- Where
- 1 siteUnited States
- Study dates
- 2 May 2025to 19 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 105 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
- Resides in the United States
- Endorses better overall health as a primary desire
- Has the opportunity for at least 30% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Who cannot join
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
- Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
Show all 12Show fewer
- Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
- o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
- Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
- o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
- Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
- Lack of reliable daily access to the internet
Trial locations and contacts
1 site in 1 country.
United States1 site
Radicle Science, Inc
Del Mar, California, 92014-2605
About this study
Official title: Radicle HealthTM 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Overall Health
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on overall health
Read the detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.
Eligible participants will (1) endorse a desire for better overall health, (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
- Conditions
- Overall Health
- Being tested
- Placebo control 7.1.0, Health Active Product 7.1.1 usage, Health Active Product 7.1.2 usage, Placebo control 7.2.0, Health Active Product 7.2.1 usage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo control 7.1.0Dietary supplement
Participants will use their placebo control 7.1.0 as directed for a period of 6 weeks.
Health Active Product 7.1.1 usageDietary supplement
Participants will use their Radicle Health Active Study Product 7.1.1 as directed for a period of 6 weeks.
Health Active Product 7.1.2 usageDietary supplement
Participants will use their Radicle Health Active Study Product 7.1.2 as directed for a period of 6 weeks.
Placebo control 7.2.0Dietary supplement
Participants will use their placebo control 7.2.0 as directed for a period of 6 weeks.
Health Active Product 7.2.1 usageDietary supplement
Participants will use their Radicle Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo control 7.1.0 | Placebo comparator | Health product 7.1.0 - control Receives: Dietary Supplement: Placebo control 7.1.0 |
| Active product 7.1.1 | Experimental | Health product 7.1.1 - active product 1 Receives: Dietary Supplement: Health Active Product 7.1.1 usage |
| Active product 7.1.2 | Experimental | Health product 7.1.2 - active product 2 Receives: Dietary Supplement: Health Active Product 7.1.2 usage |
| Placebo control 7.2.0 | Placebo comparator | Health product 7.2.0 - control Receives: Dietary Supplement: Placebo control 7.2.0 |
| Active product 7.2.1 | Experimental | Health product 7.2.1 - active product 1 Receives: Dietary Supplement: Health Active Product 7.2.1 usage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in overall health Profile
Difference between rates of change over time in overall health score as assessed by Patient Reported Outcome Measurement System (PROMIS) 29+2 Profile (PROPr consists of 7 health domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognitive function abilities; PROPr t-score score range = -.022 to 1; higher scores indicate greater overall health)
Measured: 7 weeks
Secondary outcomes (9)
Minimal clinical importance difference (MCID) in overall health-related quality of life
Likelihood of achieving a MCID in digestion-related quality of life, as measured by (PROMIS) 29+2 Profile (PROPr consists of 7 health domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognitive function abilities; PROPr t-score score range = -.022 to 1; higher scores indicate greater overall health)
Measured: 7 weeks
Change in sexual health - female
Difference between rates of change over time in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Brief Profile Sexual Function and Satisfaction Survey [female version consists of 8 health domains: interest in sexual activity (score range = 2-10; higher scores indicate greater interest), vaginal lubrication (score range = 2-10; higher scores indicate better lubrication), vaginal discomfort (score range = 2-10; higher scores indicate more discomfort), vaginal discomfort - labial (score range = 1-5; higher scores indicate more discomfort), vaginal discomfort - clitoral (score range = 1-4; higher scores indicate more discomfort), orgasm ability (score range = 1-5; higher scores indicate more ability), orgasm pleasure (score range = 1-5; higher scores indicate more pleasure), satisfaction with sex life (score range = 2-10; higher scores indicate more satisfaction)]
Measured: 7 weeks
Change in sexual health - male
Difference between rates of change over time in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Brief Profile Sexual Function and Satisfaction Survey [male version consists of 5 health domains: interest in sexual activity (score range = 2-10; higher scores indicate greater interest), erectile function (score range = 2-10; higher scores indicate better erectile function), orgasm ability (score range = 1-5; higher scores indicate more ability), orgasm pleasure (score range = 1-5; higher scores indicate more pleasure), satisfaction with sex life (score range = 2-10; higher scores indicate more satisfaction)]
Measured: 7 weeks
Change in GI-related Quality of Life (QOL)
Difference between rates of change over time in GI-related QOL as assessed by Digestion-associated QOL Questionnaire (DGLQ) (score range = 0-9; with higher scores corresponding to worse GI-related QOL)
Measured: 7 weeks
Change in mood (emotion distress-depression)
Difference between rates of change over time in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
Measured: 7 weeks
Minimal clinically important difference (MCID) in GI-related QOL
Likelihood of experiencing minimal clinically important difference in GI-related QOL score as assessed by Digestion-associated QOL Questionnaire (DGLQ) (score range = 0-9; with higher scores corresponding to worse GI-related QOL)
Measured: 7 weeks
Minimal clinically important difference (MCID) in mood (emotional distress-depression)
Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
Measured: 7 weeks
Minimal clinically important difference (MCID) in sexual health - female
Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Brief Profile Sexual Function and Satisfaction Survey [female version consists of 8 health domains: interest in sexual activity (score range = 2-10; higher scores indicate greater interest), vaginal lubrication (score range = 2-10; higher scores indicate better lubrication), vaginal discomfort (score range = 2-10; higher scores indicate more discomfort), vaginal discomfort - labial (score range = 1-5; higher scores indicate more discomfort), vaginal discomfort - clitoral (score range = 1-4; higher scores indicate more discomfort), orgasm ability (score range = 1-5; higher scores indicate more ability), orgasm pleasure (score range = 1-5; higher scores indicate more pleasure), satisfaction with sex life (score range = 2-10; higher scores indicate more satisfaction)]
Measured: 7 weeks
Minimal clinically important difference (MCID) in sexual health - male
Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Brief Profile Sexual Function and Satisfaction Survey [male version consists of 5 health domains: interest in sexual activity (score range = 2-10; higher scores indicate greater interest), erectile function (score range = 2-10; higher scores indicate better erectile function), orgasm ability (score range = 1-5; higher scores indicate more ability), orgasm pleasure (score range = 1-5; higher scores indicate more pleasure), satisfaction with sex life (score range = 2-10; higher scores indicate more satisfaction)]
Measured: 7 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2025
- Study start2 May 2025
- Primary completion19 Sep 2025
- Study completion19 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overall HealthStudies of the same condition, open and under way.
- More trials run by Radicle ScienceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,700 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radicle Science
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Susan Hewlings, Principal investigator, Radicle Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06989710
- Sponsor's protocol ID
- RADX-P-2405
- Status last verified
- Jun 2025
- First submitted
- 14 Apr 2025
- Last updated
- 6 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will not be shared with researchers outside of Radicle Collaborators on this study.
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radicle HealthTM 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Overall Health
- ClinicalTrials.gov ID
- NCT06989710
- Acronym / sponsor ID
- RADX-P-2405
- Conditions
- Overall Health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,700 participants (actual)
- Lead sponsor
- Radicle ScienceIndustry (pharma, biotech, devices)
- Study start
- 2 May 2025 (actual)
- Primary completion
- 19 Sep 2025 (actual)
- Study completion
- 19 Sep 2025 (actual)
- First posted
- 25 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on overall health
Detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.
Eligible participants will (1) endorse a desire for better overall health, (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
- Model description
- Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
| Arm | Type | Receives |
|---|---|---|
| Placebo control 7.1.0 | Placebo comparator | Dietary Supplement: Placebo control 7.1.0Health product 7.1.0 - control |
| Active product 7.1.1 | Experimental | Dietary Supplement: Health Active Product 7.1.1 usageHealth product 7.1.1 - active product 1 |
| Active product 7.1.2 | Experimental | Dietary Supplement: Health Active Product 7.1.2 usageHealth product 7.1.2 - active product 2 |
| Placebo control 7.2.0 | Placebo comparator | Dietary Supplement: Placebo control 7.2.0Health product 7.2.0 - control |
| Active product 7.2.1 | Experimental | Dietary Supplement: Health Active Product 7.2.1 usageHealth product 7.2.1 - active product 1 |
Who may qualify
- Ages
- 21 to 105 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
- Resides in the United States
- Endorses better overall health as a primary desire
- Has the opportunity for at least 30% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Key exclusion criteria (12 listed)
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo control 7.1.0Participants will use their placebo control 7.1.0 as directed for a period of 6 weeks. | Dietary supplement | Placebo control 7.1.0 |
| Health Active Product 7.1.1 usageParticipants will use their Radicle Health Active Study Product 7.1.1 as directed for a period of 6 weeks. | Dietary supplement | Active product 7.1.1 |
| Health Active Product 7.1.2 usageParticipants will use their Radicle Health Active Study Product 7.1.2 as directed for a period of 6 weeks. | Dietary supplement | Active product 7.1.2 |
| Placebo control 7.2.0Participants will use their placebo control 7.2.0 as directed for a period of 6 weeks. | Dietary supplement | Placebo control 7.2.0 |
| Health Active Product 7.2.1 usageParticipants will use their Radicle Health Active Study Product 7.2.1 as directed for a period of 6 weeks. | Dietary supplement | Active product 7.2.1 |
Primary outcome
Change in overall health Profile
Time frame: 7 weeks
Difference between rates of change over time in overall health score as assessed by Patient Reported Outcome Measurement System (PROMIS) 29+2 Profile (PROPr consists of 7 health domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognitive function abilities; PROPr t-score score range = -.022 to 1; higher scores indicate greater overall health)
9 secondary outcomes
Minimal clinical importance difference (MCID) in overall health-related quality of life
Time frame: 7 weeks
Change in sexual health - female
Time frame: 7 weeks
Change in sexual health - male
Time frame: 7 weeks
Change in GI-related Quality of Life (QOL)
Time frame: 7 weeks
Change in mood (emotion distress-depression)
Time frame: 7 weeks
Minimal clinically important difference (MCID) in GI-related QOL
Time frame: 7 weeks
Minimal clinically important difference (MCID) in mood (emotional distress-depression)
Time frame: 7 weeks
Minimal clinically important difference (MCID) in sexual health - female
Time frame: 7 weeks
Minimal clinically important difference (MCID) in sexual health - male
Time frame: 7 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2025.
- Radicle Science, IncLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data will not be shared with researchers outside of Radicle Collaborators on this study.
Related trials for Overall Health
Not yet recruiting
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
Menopause, Menopausal Symptoms
RecruitingPhase 1
Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults
HIV
Active, not recruitingPhase 4
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Severe Hemophilia A, Moderate Hemophilia A
Not yet recruitingPhase 4
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
Obesity, Childhood
Recruiting
Prospective Human Study Evaluating Changes in Markers of Detoxification, Overall Physical and Mental Health, and Fatigue Following Supplementation With CellCore Protocols
Environmental Toxins, General Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan Hewlings principal investigator
Radicle Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Health Active Product 7.1.1 usage, Health Active Product 7.1.2 usage and Health Active Product 7.2.1 usage in people with Overall Health, run by Radicle Science at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in overall health Profile (time frame: 7 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2025.